Surface Ophthalmics is a Pleasanton, CA-based pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases. Led by President and CEO Kamran Hosseini, MD, PhD, the company is advancing three ophthalmic product candidates: SURF-100 for chronic dry eye, SURF-200 for acute dry eye, and SURF-201 for pain and inflammation following ocular surgery. These programs utilize the Klarity delivery vehicle developed by Richard L. Lindstrom, MD, which is designed to enhance patient comfort and protect and rehabilitate the ocular surface. The company raised $25M from a mix of new and existing investors, including institutional, healthcare-focused and other accredited investors and members of the Surface board. Surface intends to use the funds to advance its clinical programs in ocular diseases. After completing current Phase II studies, the company plans to begin enrolling patients in Phase III trials targeting FDA approval for all three candidates. Surface Pharmaceuticals, led by CEO Kamran Hosseini MD, PhD, focuses on development and commercialization of therapeutics for ocular surface diseases using the Section 505(b)(2) regulatory pathway. Its current pipeline consists of three proprietary drug candidates: topical eye drops SURF-100 and SURF-200, which use a patented delivery vehicle invented by Dr. Richard Lindstrom, and SURF-300, a patent-pending oral capsule. The company plans to seek FDA approval for its three candidates for up to five indications, including treatments for Dry Eye Disease. Surface intends to use the proceeds of the financing to advance its clinical development programs and for general corporate purposes. At the time of the report the company was an affiliated entity of Imprimis Pharmaceuticals (NASDAQ: IMMY). The closing of the financing is expected to allow Surface to be deconsolidated from Imprimis and become a separately financed and managed entity.

Total raised

$45M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2021